SNIPR Biome’s data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

Avatar photo
Business Intelligence

SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients            SNIPR001 represents the first CRISPR- therapeutic developed to specifically remove E. coli in the human gut            In vitro studies showed SNIPR001 displaying high specificity towards E. coli and activity in multi-drug resistant strains

COPENHAGEN, Denmark, May 5, 2023 /PRNewswire/ —  SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces today that Nature Biotechnology has published research findings from its preclinical work on  SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, in the human gastrointestinal tract.

The emergence of antibiotic-resistant pathogens represents a major global challenge. In numerous disease areas, current medical practice relies on increasingly aggressive therapies, which can sometimes result in patients experiencing life-threatening infections, including those caused by antibiotic-resistant bacteria. This issue is often under-recognized in contemporary healthcare ecosystems and the escalating threat of antimicrobial resistance has the potential to lead to a significant health care challenge in the future.

SNIPR001’s mechanism of action, as a CRISPR-armed phage therapeutic that specifically targets and eradicates E. coli in the gut, is designed to prevent infections from spreading into the bloodstream and represents a promising advancement against antibiotic-resistant pathogens. This publication represents a significant validation of the ground-breaking technology research done at the laboratories and collaborators of SNIPR Biome and also opens up the possibility of targeting other pathogens.

Dr Christian Grøndahl CEO and co-founder of SNIPR Biome, commented: “This therapy has the potential to revolutionize the way we prevent and treat infections, and we believe it could potentially serve as a model for developing similar therapies that target other life-threatening pathogens. By integrating different aspects of drug development, from bioinformatics to regulatory requirements, we have been able to leverage our CRISPR-Cas technology to generate a whole new class of drugs.”

 Dr Eric van der Helm VP of Scientific Affairs of SNIPR Biome, commented:  “This article represents a true team effort over the last few years of many of our employees and collaborators to integrate all aspects of drug development ranging from bioinformatics, synthetic biology, in vitro assays, in vivo models to regulatory requirements and CMC. With more than a million deaths annually attributed to antimicrobial resistance, we are committed to developing precision medicines that will make a significant impact in the fight against this global health threat.”

 SNIPR001 has been granted a Fast-Track designation by the US Food and Drug Administration (“FDA”), was supported by CARB-X, and SNIPR is currently conducting a Phase 1 trial in the US to evaluate its safety and efficacy in reducing E. coli in the gut without disturbing the overall gut microbiome (NCT05277350).

Article citation: Gencay, Y.E., Jasinskytė, D., Robert, C. et al. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice. Nat Biotechnol (2023).


Dr Christian Grøndahl, Co-founder and CEO
E-mail: [email protected] 
Mobile: +45 20202747 
Please follow us on LinkedIn & Twitter: @SNIPRBiome

Consilium Strategic Communications
Tracy Cheung, Chris Welsh, Davide Salvi
Tel: +44 (0) 203 709 5700
[email protected]

View original content:




《澳門商業雜誌》和本集團Project Asia Corporation於本周五(5月24日)舉辦酒會,慶祝成立20周年。 澳門行政長官賀一誠致函《澳門商業雜誌》,對雜誌成立二十周年表示祝賀。






引用Tomasi de Lampedusa的一句名言:為了有所改變,我們必須讓一切保持原狀。